Colon Pharmaceutical announced on the morning of January 5 that the company's holding subsidiary Colonbotai's antibody-conjugate drug, lukansastuzumab, combined with MSD's anti-programmed cell death protein 1 monoclonal antibody pabolizumab first-line treatment with programmed cell death ligand 1 tumor ratio score of at least 1% negative and anaplastic lymphoma kinase negative for locally advanced or metastatic non-small cell lung cancer has been awarded breakthrough therapy by the China Drug Administration Drug Evaluation Center. In addition, the new drug clinical trial application for SKB105, a targeted integrin beta-6 antibody conjugate drug independently developed by Colunbotai, has been approved by the Drug Evaluation Center of the State Drug Administration of China to treat advanced solid tumors.

Colon Pharmaceutical announced on the morning of January 5 that the company's holding subsidiary Colonbotai's antibody-conjugate drug, lukansastuzumab, combined with MSD's anti-programmed cell death protein 1 monoclonal antibody pabolizumab first-line treatment with programmed cell death ligand 1 tumor ratio score of at least 1% negative and anaplastic lymphoma kinase negative for locally advanced or metastatic non-small cell lung cancer has been awarded breakthrough therapy by the China Drug Administration Drug Evaluation Center. In addition, the new drug clinical trial application for SKB105, a targeted integrin beta-6 antibody conjugate drug independently developed by Colunbotai, has been approved by the Drug Evaluation Center of the State Drug Administration of China to treat advanced solid tumors.